RecruitingRecruiting
Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study
NCT07669935 · Medicines360
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Multi-Site, Prospective, Two-Part Longitudinal, Observational Cohort Study Of Pregnant Women To Evaluate Biomarkers For Prediction Of Pregnancy Complications
About this study
ASPIRE will be a multi-site, prospective, two-part longitudinal, noninterventional observational cohort study of nulliparous singleton pregnant women to evaluate biomarkers from blood and ocular imaging for prediction of pregnancy complications \[i.e., preeclampsia (PE), fetal growth restriction (FGR), and gestational diabetes (GDM)\] and risk of adverse outcomes.
Eligibility criteria
Inclusion Criteria:
* Age ≥18 years
* Nulliparous (no previous births ≥20wk GA)
* Single viable fetus at the dating ultrasound scan with an ultrasound estimated gestational age of 10 0/7-17 6/7 weeks of gestation
* Ability to consent and comply with study procedures and follow-up
Exclusion Criteria:
* Multiple gestation
* Inability to provide blood
* Known fetal chromosomal abnormalities or structural Anomaly (a structural or functional defect with the following three characteristics: 1) of prenatal origin; 2) present at the time of live birth or fetal demise, or in utero; 3) affecting (or has the propensity to affect) the health, survival, or physical or cognitive functioning of the individual
* Known or anticipated inability to complete study follow-up through delivery at the study site (e.g., planned relocation, transfer of obstetric care to a non-participating institution, or other circumstances making delivery outcome data unavailable)
* Current or recent (within two months) participation in an interventional clinical study.
Study design
Enrollment target: 5500 participants
Age groups: adult, older_adult
Timeline
Starts: 2026-09-08
Estimated completion: 2028-12-01
Last updated: 2026-11-10
Interventions
Other: None (this is an observational study with no intervention)
Primary outcomes
- • Identification of cut-offs for risk stratification for conditions such as preeclampsia, fetal growth restriction and gestational diabetes at different timepoints in gestation. (From enrollment to approximately 4 weeks postpartum)
- • To perform clinical validation of blood-based biomarkers using cut-offs at different timepoints in gestation. (From enrollment to approximately 4 weeks postpartum)
- • To develop a retinal imaging algorithm for risk prediction for preeclampsia. (From enrollment to approximately 4 weeks postpartum)
Sponsor
Medicines360 · other
Contacts & investigators
ContactCarrie Fralick, MS · contact · Carie.Fralick@womans.org · 225-512-5546
All locations (5)
Yale New Haven Health SystemRecruiting
Bridgeport, Connecticut, United States
Yale New Haven Health SystemRecruiting
New Haven, Connecticut, United States
Woman's HospitalRecruiting
Baton Rouge, Louisiana, United States
St. Lawrence HealthActive Not Recruiting
Potsdam, New York, United States
UTHealth HoustonRecruiting
Houston, Texas, United States